LDLR can be subjected to post-translational degradation by proprotein convertase subtilisin/kexin type 9 (PCSK9), a liver-derived solute factor that binds to the extracellular domain of LDLR, reducing LDL internalization and leading to hyperlipidemia. This evidence concerns the gene PCSK9 and hyperlipidemia.